NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announces the completion of the 24-week treatment phase of the company’s Phase 3 registration study ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE